Clearmind Medicine (CMND) News Today $1.40 +0.04 (+2.94%) (As of 11/4/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Clearmind Medicine Inc.: Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical SiteOctober 11, 2024 | finanznachrichten.deClearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical SiteOctober 10, 2024 | globenewswire.comClearmind Medicine patents new addiction treatmentSeptember 18, 2024 | uk.investing.comClearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination TherapySeptember 16, 2024 | globenewswire.comClearmind Medicine files patent for PTSD treatment compoundsSeptember 15, 2024 | uk.investing.comClearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD TreatmentSeptember 12, 2024 | globenewswire.comClearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination TreatmentSeptember 6, 2024 | globenewswire.comClearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination TreatmentAugust 29, 2024 | globenewswire.comCould Psychedelics End Binge Drinking? A Breakthrough Patent Says YesAugust 24, 2024 | msn.comClearmind Medicine Granted U.S. Patent Approval for Binge Behavior TreatmentAugust 21, 2024 | globenewswire.comClearmind, Yissum Apply for International Patent for PsychedelicsAugust 16, 2024 | marketwatch.comClearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental DisordersAugust 16, 2024 | globenewswire.comClearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss DrugAugust 6, 2024 | globenewswire.comClearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference: Presented Industry Leaders its Groundbreaking ResearchJuly 31, 2024 | globenewswire.comClearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage ProductJuly 19, 2024 | globenewswire.comClearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for AlcoholismJuly 16, 2024 | globenewswire.comClearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-lossJuly 16, 2024 | globenewswire.comClearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 ConferenceJuly 12, 2024 | globenewswire.comClearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors TreatmentJune 28, 2024 | globenewswire.comClearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD TreatmentJune 20, 2024 | globenewswire.comClearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based DrinkJune 11, 2024 | globenewswire.comClearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage ProductMay 10, 2024 | globenewswire.comWhy Clearmind Medicine Stock Is Moving HigherMay 7, 2024 | msn.comClearmind Medicine Inc.: Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD TreatmentMay 7, 2024 | finanznachrichten.deClearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD TreatmentMay 7, 2024 | globenewswire.comClearmind Medicine Inc.: Clearmind Applies to Cease Being a Reporting Issuer in CanadaMay 1, 2024 | finanznachrichten.deClearmind Applies to Cease Being a Reporting Issuer in CanadaApril 30, 2024 | globenewswire.comClearmind signs agreement for psychedelic compounds for mental disorders treatmentApril 17, 2024 | msn.comClearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental DisordersApril 17, 2024 | finance.yahoo.comClearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental DisordersApril 17, 2024 | globenewswire.comClearmind Medicine advances trial for alcohol use disorder treatmentApril 11, 2024 | uk.investing.comClearmind Medicine Inc.: Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating DisordersApril 10, 2024 | finanznachrichten.deClearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating DisordersApril 10, 2024 | globenewswire.comClearmind Medicine Inc.: Clearmind Medicine CEO Issues Letter to ShareholdersApril 9, 2024 | finanznachrichten.deClearmind Medicine CEO Issues Letter to ShareholdersApril 9, 2024 | globenewswire.comClearmind Medicine files tenth patent for depression treatmentMarch 29, 2024 | uk.investing.comSciSparc Ltd: SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating DepressionMarch 27, 2024 | finanznachrichten.deClearmind Medicine Inc.: Clearmind Medicine Announces International Patent Application for Preventing and Treating DepressionMarch 27, 2024 | finanznachrichten.deClearmind Medicine Announces International Patent Application for Preventing and Treating DepressionMarch 27, 2024 | globenewswire.comBreakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in ChinaMarch 19, 2024 | globenewswire.comClearmind Medicine Inc.: Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities ExchangeMarch 13, 2024 | finanznachrichten.deClearmind Medicine Inc.: Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical TrialMarch 13, 2024 | finanznachrichten.deClearmind Medicine receives nod for delisting of shares from Canadian Securities ExchangeMarch 13, 2024 | msn.comClearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical TrialMarch 13, 2024 | globenewswire.comClearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities ExchangeMarch 13, 2024 | globenewswire.comPodcast: Clearmind's Non-Hallucinogenic Psychoactive Molecule Could Become A Solution For Addictive BehaviorsMarch 12, 2024 | msn.comEXCLUSIVE: Psychedelic-Focused Firm Clearmind Medicine Submits Three New International Patent Applications For MDMA, Ibogaine And Ketamine CompoundsFebruary 27, 2024 | msn.comClearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine CompoundsFebruary 27, 2024 | globenewswire.comClearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use DisorderFebruary 23, 2024 | globenewswire.comClearmind Medicine Stock (NASDAQ:CMND), Quotes and News SummaryFebruary 22, 2024 | benzinga.com Get Clearmind Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for CMND and its competitors with MarketBeat's FREE daily newsletter. Email Address The Crypto That’s Making Wall Street Sweat (Ad)The Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech giants are quietly integrating it. Venture capitalists are scrambling to invest. Click here to discover our #1 crypto for the market right now – poised for massive growth CMND Media Mentions By Week CMND Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CMND News Sentiment▼0.000.46▲Average Medical News Sentiment CMND News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CMND Articles This Week▼02▲CMND Articles Average Week Get Clearmind Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for CMND and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SNGX News Today ATHE News Today CDT News Today UPXI News Today RNAZ News Today ABVC News Today CYCN News Today COEP News Today PULM News Today VIRX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CMND) was last updated on 11/4/2024 by MarketBeat.com Staff From Our Partners2 sentences that change everything you THOUGHT you knew about tradingIf you're like most people, on Friday morning you'll probably follow your set routine: Wake up... eat breakfas...Investing Daily | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredA Totally New ‘Income Coin’Buckle up… Because this might shatter everything you thought you knew about "income trading." In fact, i...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clearmind Medicine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clearmind Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
